RE-DUAL

Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation - The New England Journal of Medicine - 2017

Brief Summary:

In patients with nonvalvular AF undergoing PCI for coronary artery disease, dual therapy with a thienopyridine antiplatelet and dabigatran is associated with an 11.5% absolute reduction in major and clinically relevant non-major bleeding when compared to triple therapy. Dual therapy was also associated with overall similar rates of thrombosis, although a pooled analysis including both doses of dabigatran dual therapy revealed a modest and non-significant 1.1% absolute increase in thromboembolic events or death.

Reference: http://www.ncbi.nlm.nih.gov/pubmed/28844193